Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 20, 2017
What is the competitive landscape for UCB INC, and what generic alternatives to UCB INC drugs are available?
UCB INC has forty-eight approved drugs.| Patents: | 15 |
| Tradenames: | 32 |
| Ingredients: | 24 |
| NDAs: | 48 |
| Drug Master File Entries: (click here to view) | 1 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
rotigotine | Extended-release Transdermal Film | 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr | NEUPRO | 11/26/2013 |
lacosamide | Oral Solution | 10 mg/mL | VIMPAT | 10/29/2012 |
lacosamide | Tablets | 50 mg, 100 mg, 150 mg, and 200 mg | VIMPAT | 10/29/2012 |
levetiracetam | Extended-release Tablets | 1000 mg | KEPPRA XR | 1/7/2011 |
metformin hydrochloride | Extended-release Capsules | 40 mg | METADATE CD | 3/15/2007 |
levetiracetam | Tablets | 1000 mg | KEPPRA | 1/24/2007 |
alprazolam | Orally Disintegrating Tablets | 0.25 mg, 0.5 mg, 1 mg and 2 mg | NIRAVAM | 12/27/2005 |
metformin hydrochloride | Extended-release Capsules | 10 mg, 20 mg and 30 mg | METADATE CD | 5/13/2005 |
moexipril hydrochloride and hydrochlorothiazide | Tablets | 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg | UNIRETIC | 1/15/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,713,635 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | ► Subscribe | |||||||||||||||||||||||||||
| 7,217,826 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | ► Subscribe | |||||||||||||||||||||||||||
| 6,969,770 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | ► Subscribe | |||||||||||||||||||||||||||
| 6,048,899 | Anticonvulsant enantiomeric amino acid derivatives | ► Subscribe | |||||||||||||||||||||||||||
| 6,858,740 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | ► Subscribe | |||||||||||||||||||||||||||
| 8,034,958 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | ► Subscribe | |||||||||||||||||||||||||||
| 7,863,316 | Extended release formulation of Levetiracetam | ► Subscribe | |||||||||||||||||||||||||||
| 5,773,475 | Anticonvulsant enantiomeric amino acid derivatives | ► Subscribe | |||||||||||||||||||||||||||
| 6,806,287 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | ► Subscribe | |||||||||||||||||||||||||||
| 7,692,028 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malaysia | 138966 | ► Subscribe | |||||||||||||||||||||||||||
| China | 101111245 | ► Subscribe | |||||||||||||||||||||||||||
| Australia | 746856 | ► Subscribe | |||||||||||||||||||||||||||
| Ukraine | 89216 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2248317 | ► Subscribe | |||||||||||||||||||||||||||
| Germany | 60143493 | ► Subscribe | |||||||||||||||||||||||||||
| Russian Federation | 2002124865 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 101016914 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 4769756 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2355140 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2006 | Austria | ► Subscribe | PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 - EU/1/05/331/013 20060215 | ||||||||||||||||||||||||||
| C0025 | France | ► Subscribe | PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215 | ||||||||||||||||||||||||||
| 2006 00020 | Denmark | ► Subscribe | |||||||||||||||||||||||||||
| 24/2006 | Austria | ► Subscribe | PRODUCT NAME: ROTIGOTINE | ||||||||||||||||||||||||||
| C026/2006 | Ireland | ► Subscribe | SPC026/2006:, EXPIRES: 20210214 | ||||||||||||||||||||||||||
| C/GB12/058 | United Kingdom | ► Subscribe | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 | ||||||||||||||||||||||||||
| 1033978/01 | Switzerland | ► Subscribe | PRODUCT NAME: ROTIGOTINE; REGISTRATION NUMBER/DATE: SWISSMEDIC 57417 27.09.2006 | ||||||||||||||||||||||||||
| C/GB99/008 | United Kingdom | ► Subscribe | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 | ||||||||||||||||||||||||||
| C001/2009 | Ireland | ► Subscribe | SPC001/2009: 20091013, EXPIRES: 20220316 | ||||||||||||||||||||||||||
| 2009 00001 | Denmark | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,694 others who get our Drug Patent Expiration Alerts:
